|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:access
|
patient assistance program
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
January 31, 2012
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Kalydeco
|
|
gptkbp:can_be_combined_with
|
gptkb:lumacaftor
gptkb:tezacaftor
|
|
gptkbp:chemical_formula
|
C24 H26 Cl F3 N2 O
|
|
gptkbp:clinical_trial
|
Phase 3
|
|
gptkbp:clinical_use
|
long-term treatment
|
|
gptkbp:contraindication
|
hypersensitivity to ivacaftor
|
|
gptkbp:discovered_by
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:dosage_form
|
tablets
|
|
gptkbp:drug_interactions
|
strong CYP3 A inducers
strong CYP3 A inhibitors
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:financial_support
|
gptkb:financial_assistance
gptkb:educational_resources
support groups
|
|
gptkbp:formulation
|
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ivacaftor
|
|
gptkbp:indication
|
G551 D mutation in CFTR gene
|
|
gptkbp:invention
|
2027
patented
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:marketed_as
|
gptkb:Canada
gptkb:European_Union
gptkb:United_States
|
|
gptkbp:mechanism_of_action
|
potentiator of CFTR
|
|
gptkbp:metabolism
|
gptkb:CYP3_A4
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:patient_population
|
adults
children over 2 years
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_guidance_on
|
recommended for specific mutations
|
|
gptkbp:research
|
combination therapies
long-term safety
efficacy in children
real-world effectiveness
|
|
gptkbp:research_areas
|
cystic fibrosis therapies
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:safety_measures
|
liver function tests
respiratory events
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
diarrhea
rash
elevated liver enzymes
upper respiratory tract infection
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
CFTR protein
|
|
gptkbp:used_for
|
gptkb:cystic_fibrosis
|
|
gptkbp:bfsParent
|
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Trikafta
|
|
gptkbp:bfsLayer
|
5
|